Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. is dated April 13, 2020, covering the month of April 2020. DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin, an investigational epicutaneous immunotherapy (EPIT) platform for food allergies and immune diseases. The filing primarily announces the logistics for the Ordinary and Extraordinary General Meeting scheduled for April 20, 2020.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
There are no material financial changes reported in this filing. The primary operational change is the conversion of the April 20, 2020 General Meeting to a closed virtual session due to the COVID-19 pandemic and French government health instructions limiting gatherings.
Guidance, Outlook, and Risks
- Management Commentary: The Board of Directors emphasized the safety of shareholders and employees as the driver for holding the meeting virtually.
- Risks and Contingencies: The filing highlights the impact of the coronavirus pandemic on corporate governance procedures, necessitating remote voting and webcasting.
- Unusual Items: The meeting will be conducted in French without physical presence. Shareholders must vote via proxy, email through the Votaccess platform, or downloadable forms.
- Outlook: No specific business outlook or guidance was provided in this text.
Key Facts for Investor Verification
- General Meeting Date: April 20, 2020, at 8:30 a.m. CEST.
- Meeting Format: Closed virtual session (no physical attendance).
- Voting Deadline: Questions must be submitted by 3:00 p.m. CEST on April 17, 2020.
- Record Date: Shareholders of record as of April 3, 2020.
- Webcast Access: Live audio and recorded webcast available on the company website.